Advertisement
Advertisement

JSPR

JSPR logo

Jasper Therapeutics, Inc. Common Stock

1.48
USD
Sponsored
-0.07
-4.84%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

1.50

+0.02
+1.36%

JSPR Earnings Reports

Positive Surprise Ratio

JSPR beat 9 of 17 last estimates.

53%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.68
Implied change from Q3 25 (Revenue/ EPS)
--
/
-45.60%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-58.02%

Jasper Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, JSPR reported earnings of -1.25 USD per share (EPS) for Q3 25, missing the estimate of -1.23 USD, resulting in a -0.87% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.68 USD, with revenue projected to reach -- USD, implying an decrease of -45.60% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Jasper Therapeutics, Inc. Common Stock reported EPS of -$1.25, missing estimates by -0.87%, and revenue of $0.00, 0% as expectations.
The stock price moved -- 0%, changed from $1.78 before the earnings release to $1.78 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 9 analysts, Jasper Therapeutics, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement